FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312093997> ?p ?o ?g. }

• W4312093997 endingPage "122463" @default.
• W4312093997 startingPage "122463" @default.
• W4312093997 abstract "COVID-19 is caused by the infection of the lungs by SARS-CoV-2. Monoclonal antibodies, such as sotrovimab, showed great efficiency in neutralizing the virus before its internalization by lung epithelial cells. However, parenteral routes are still the preferred route of administration, even for local infections, which requires injection of high doses of antibody to reach efficacious concentrations in the lungs. Lung administration of antibodies would be more relevant requiring lower doses, thus reducing the costs and the side effects. But aerosolization of therapeutic proteins is very challenging, as the different processes available are harsh and trigger protein aggregation and conformational changes. This decreases the efficiency of the treatment, and can increase its immunogenicity. To address those issues, we developed a series of new excipients composed of a trehalose core, a succinyl side chain and a hydrophobic carbon chain (from 8 to 16 carbons). Succinylation increased the solubility of the excipients, allowing their use at relevant concentrations for protein stabilization. In particular, the excipient with 16 carbons (C16TreSuc) used at 5.6 mM was able to preserve colloidal stability and antigen-binding ability of sotrovimab during the nebulization process. It could also be used as a cryoprotectant, allowing storage of sotrovimab in a lyophilized form during weeks. Finally, we demonstrated that C16TreSuc could be used as an excipient to stabilize antibodies for the treatment against COVID-19, by in vitro and in vivo assays. The presence of C16TreSuc during nebulization preserved the neutralization capacity of sotrovimab against SARS-CoV-2 in vitro; an increase of its efficacy was even observed, compared to the non-nebulized control. The in vivo study also showed the wide distribution of sotrovimab in mice lungs, after nebulization with 5.6 mM of excipient. This work brings a solution to stabilize therapeutic proteins during storage and nebulization, making pulmonary immunotherapy possible in the treatment of COVID-19 and other lung diseases." @default.
• W4312093997 created "2023-01-04" @default.
• W4312093997 creator A5001881567 @default.
• W4312093997 creator A5017125137 @default.
• W4312093997 creator A5017429669 @default.
• W4312093997 creator A5023170919 @default.
• W4312093997 creator A5034520476 @default.
• W4312093997 creator A5040902955 @default.
• W4312093997 creator A5052400382 @default.
• W4312093997 creator A5055274635 @default.
• W4312093997 creator A5058103666 @default.
• W4312093997 creator A5060777108 @default.
• W4312093997 creator A5068025266 @default.
• W4312093997 creator A5080053406 @default.
• W4312093997 creator A5082925023 @default.
• W4312093997 creator A5091340307 @default.
• W4312093997 date "2023-01-01" @default.
• W4312093997 modified "2023-09-30" @default.
• W4312093997 title "Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody" @default.
• W4312093997 cites W1973666722 @default.
• W4312093997 cites W1986885117 @default.
• W4312093997 cites W1993654128 @default.
• W4312093997 cites W1995651579 @default.
• W4312093997 cites W2004648579 @default.
• W4312093997 cites W2005149540 @default.
• W4312093997 cites W2011749765 @default.
• W4312093997 cites W2012722667 @default.
• W4312093997 cites W2021591903 @default.
• W4312093997 cites W2030592774 @default.
• W4312093997 cites W2038373191 @default.
• W4312093997 cites W2039647080 @default.
• W4312093997 cites W2040454339 @default.
• W4312093997 cites W2040693395 @default.
• W4312093997 cites W2049281680 @default.
• W4312093997 cites W2051696465 @default.
• W4312093997 cites W2052037332 @default.
• W4312093997 cites W2054187364 @default.
• W4312093997 cites W2056538420 @default.
• W4312093997 cites W2059564760 @default.
• W4312093997 cites W2060403466 @default.
• W4312093997 cites W2061530050 @default.
• W4312093997 cites W2064095468 @default.
• W4312093997 cites W2066404267 @default.
• W4312093997 cites W2067361688 @default.
• W4312093997 cites W2074467065 @default.
• W4312093997 cites W2077919900 @default.
• W4312093997 cites W2081306620 @default.
• W4312093997 cites W2081307882 @default.
• W4312093997 cites W2092075009 @default.
• W4312093997 cites W2131692566 @default.
• W4312093997 cites W2134625581 @default.
• W4312093997 cites W2143253342 @default.
• W4312093997 cites W2156350829 @default.
• W4312093997 cites W2240077590 @default.
• W4312093997 cites W2291150896 @default.
• W4312093997 cites W2531354461 @default.
• W4312093997 cites W2548676616 @default.
• W4312093997 cites W2568949398 @default.
• W4312093997 cites W2586385234 @default.
• W4312093997 cites W2602500246 @default.
• W4312093997 cites W2739954745 @default.
• W4312093997 cites W2746604201 @default.
• W4312093997 cites W2803434802 @default.
• W4312093997 cites W2886321229 @default.
• W4312093997 cites W2904228061 @default.
• W4312093997 cites W2920139773 @default.
• W4312093997 cites W2957004561 @default.
• W4312093997 cites W3008011764 @default.
• W4312093997 cites W3024520710 @default.
• W4312093997 cites W3025744748 @default.
• W4312093997 cites W3033997257 @default.
• W4312093997 cites W3048950999 @default.
• W4312093997 cites W3093146178 @default.
• W4312093997 cites W3096284144 @default.
• W4312093997 cites W3138789532 @default.
• W4312093997 cites W3148616326 @default.
• W4312093997 cites W3153515080 @default.
• W4312093997 cites W3165032628 @default.
• W4312093997 cites W3210778737 @default.
• W4312093997 cites W4220974464 @default.
• W4312093997 cites W4293512386 @default.
• W4312093997 doi "https://doi.org/10.1016/j.ijpharm.2022.122463" @default.
• W4312093997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36462738" @default.
• W4312093997 hasPublicationYear "2023" @default.
• W4312093997 type Work @default.
• W4312093997 citedByCount "0" @default.
• W4312093997 crossrefType "journal-article" @default.
• W4312093997 hasAuthorship W4312093997A5001881567 @default.
• W4312093997 hasAuthorship W4312093997A5017125137 @default.
• W4312093997 hasAuthorship W4312093997A5017429669 @default.
• W4312093997 hasAuthorship W4312093997A5023170919 @default.
• W4312093997 hasAuthorship W4312093997A5034520476 @default.
• W4312093997 hasAuthorship W4312093997A5040902955 @default.
• W4312093997 hasAuthorship W4312093997A5052400382 @default.
• W4312093997 hasAuthorship W4312093997A5055274635 @default.
• W4312093997 hasAuthorship W4312093997A5058103666 @default.
• W4312093997 hasAuthorship W4312093997A5060777108 @default.
• W4312093997 hasAuthorship W4312093997A5068025266 @default.

• next